Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.52 |
| ▸ | NPC1 | O15118 | 2/20 | 0.47 |
| ▸ | PDGFRB | P09619 | 3/20 | 0.46 |
| ▸ | MDM2 | Q00987 | 2/20 | 0.45 |
| ▸ | RET | P07949 | 2/20 | 0.43 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.43 |
| ▸ | FLT3 | P36888 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | KDR | P35968 | 1/20 | 0.42 |
| ▸ | PLK4 | O00444 | 1/20 | 0.41 |
| ▸ | PLK1 | P53350 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14658996 | 1.00 | MEN1 (0.52) | MEN1KMT2ANPC1PDGFRBMDM2 | |
| SCHEMBL223844 | 0.88 | MDM2 (0.53) | MEN1KMT2ANPC1PDGFRBMDM2 | |
| SCHEMBL29776573 | 0.88 | MDM2 (0.53) | MEN1KMT2ANPC1PDGFRBMDM2 | |
| SCHEMBL250345 | 0.88 | MDM2 (0.53) | MEN1KMT2ANPC1PDGFRBMDM2 | |
| SCHEMBL29443894 | 0.88 | MDM2 (0.53) | MEN1KMT2ANPC1PDGFRBMDM2 | |
| SCHEMBL13469206 | 0.85 | PIM1 (0.49) | MEN1KMT2ANPC1PDGFRBMDM2 | |
| SCHEMBL6822268 | 0.85 | NPC1 (0.47) | MEN1KMT2ANPC1PDGFRBMDM2 | |
| SCHEMBL2739255 | 0.85 | NPC1 (0.47) | MEN1KMT2ANPC1PDGFRBMDM2 | |
| SCHEMBL28695546 | 0.83 | NPC1 (0.45) | MEN1KMT2ANPC1PDGFRBMDM2 | |
| SCHEMBL29875292 | 0.83 | NPC1 (0.45) | MEN1KMT2ANPC1PDGFRBMDM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8742121-B2 | Process for the preparation of small molecule inhibitors of MDM2 and intermediates used therein | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2014-06-03 | — | — | US | claimed |
| US-20130030173-A1 | PROCESS FOR THE PREPARATION OF SMALL MOLECULE INHIBITORS OF MDM2 AND INTERMEDIATES USED THEREIN | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2013-01-31 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130030173-A1 | PROCESS FOR THE PREPARATION OF SMALL MOLECULE INHIBITORS OF MDM2 AND INTERMEDIATES USED THEREIN | TP53, MDM2, CDKN1A | MEN1 2197/4885KMT2A 3347/4885NPC1 4106/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.